A PEER-REVIEWED JOURNAL OF RESEARCH AND CLINICAL MEDICINEISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Menopausal Hormonotherapy and Venous Thromboembolic Events: Is There Any Correlation?

DOI:10.31550/1727-2378-2019-166-11-68-73
For citation: Kuznetsov M.R., Papysheva O.V. Menopausal Hormonotherapy and Venous Thromboembolic Events: Is There Any Correlation? Doctor.Ru. 2019; 11(166): 68–73. DOI: 10.31550/1727-2378-2019-166-11-68-73
1 October 15:46

Objective of the Review: to discuss the available data concerning the correlation between sex hormone administration, including menopausal hormonotherapy (MHT), and venous thromboembolic events (VTEE).
Key Points: the role of estrogens and gestagens in possible venous thrombosis is discussed. The data from a large-scale observational study are presented; the study enrolled 80,396 women aged 40 to 79 years old registered in GP databases of the United Kingdom and treated with various MHT from 1997 to 2017. It is demonstrated that, as far as VTEE is concerned, the safety of a combination of estradiol and didrogesteronis not significantly different from transdermal administration, however it is 4-5 times more efficient in prevention of cardiovascular disorders (arterial hypertension, diabetes mellitus, and atherosclerotic vascular disease). Also, a combination of estradiol and didrogesteron was associated with a minimal risk of venous thrombosis, irrespective of the mode of administration (cyclic or continuous), age, and body mass index of patients. Ultra-low doses of these medications demonstrated lower risk of thrombotic complications vs. controls.
Conclusion: the correct choice of MHT can contribute to its wider use, allowing to maximally reduce the risk of severe cardiovascular events with minimal risks of VTEE.

M.R. Kuznetsov — N.I. Pirogov Russian National Research Medical University; N.E. Bauman Municipal Clinical Hospital No.29; 1 Ostrovityanov Str., Moscow, Russian Federation 117997. eLIBRARY.RU SPIN: 7146-1348. E-mail: mrkuznetsov@mail.ru

O.V. Papysheva — N.E. Bauman Municipal Clinical Hospital No.29; 2 Gospitalnaya pl., Moscow, Russian Federation 111020. E-mail: viulen@mail.ru

Contribution: Kuznetsov M.R. — thematic publications reviewing, eview of critically important intellectual material; Papysheva O.V. — thematic publications reviewing, data analysis and interpretation.

The authors declare that they do not have any conflict of interests.

Доктор.ру
1 October 15:46
LITERATURE
  1. Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П., Баринов В.Е., Бицадзе В.О., Бодыхов М.К. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 4(2). 52 с. [Andriyashkin A.V., Andriyashkin V.V., Arutyunov G.P., Barinov V.E., Bitsadze V.O., Bodykhov M.K. i dr. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiya. 2015; 4(2). 52 s. (in Russian)]
  2. García Sabrido J.L., Pacheco Sánchez D. Profilaxis de la enfermedad tromboembоlica perioperatoria en cirugta general. Cir. Esp. 2001; 69: 49–55.
  3. Duranteau J., Taccone F.S., Verhamme P., Ageno W.; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care. Eur. J. Anaesthesiol. 2018; 35(2): 142–6. DOI: 10.1097/EJA.0000000000000707
  4. Al Yami M.S., Silva M.A., Donovan J.L., Kanaan A.O. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis. J. Thromb. Thrombolysis. 2018; 45(1): 36–47. DOI: 10.1007/s11239-017-1562-5
  5. Ceballos C., Ribes C., Amado J.A., Pérez J., Garcı́a Unzueta M.T., de Berrazueta J.R. Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy. Fertil. Steril. 2000; 74(2): 268–73. DOI: 10.1016/s0015-0282(00)00627-0
  6. Salobir B.G., Keber J., Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil. Steril. 2002; 78(6): 1178–83. DOI: 10.1016/s0015-0282(02)04291-7
  7. Scarabin P.Y., Hemker H.C., Clément C., Soisson V., Alhenc-Gelas M. Increaset thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestagens. Menopause. 2011; 18(8): 873–9. DOI: 10.1097/gme.0b013e31820eee88
  8. Teede H.J., McGrath B.P., Smolich J.J., Malan E., Kotsopoulos D., Liang Y.L. et al. Postmenopausal hormone replacement therapy increaces coagulation activity and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 2000; 20(5): 1404–9. DOI: 10.1161/01.atv.20.5.1404
  9. Bastos M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M., Stijnen T. et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst. Rev. 2014; 3: CD010813. DOI: 10.1002/14651858.CD010813.pub2
  10. Lumsden M.A., Davies M., Sarri G.; Guideline Development Group for Menopause: Diagnosis and Management (NICE Clinical Guideline No. 23). Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern. Med. 2016; 176(8): 1205–6. DOI: 10.1001/jamainternmed.2016.2761
  11. Baber R.J. Panay N., Fenton A.; IMS Writing Group. IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109–50. DOI: 10.3109/13697137.2015.1129166
  12. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018; 24(7): 728–53. DOI: 10.1097/GME.0000000000001241
  13. Российское общество акушеров-гинекологов, Российская ассоциация по менопаузе. Менопауза и климактерическое состояние у женщины. Клинические рекомендации. РОАГ: КР117; 2016. 45 с. [Rossiiskoe obshchestvo akusherov-ginekologov, Rossiiskaya assotsiatsiya po menopauze. Menopauza i klimaktericheskoe sostoyanie u zhenshchiny. Klinicheskie rekomendatsii. ROAG: KR117; 2016. 45 s. (in Russian)]
  14. Marjoribanks J., Farquhar C., Roberts H., Lethaby A., Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017; 1: CD004143. DOI: 10.1002/14651858.CD004143.pub5
  15. Mohammed K., Abu Dabrh A.M., Benkhadra K., Al Nofal A., Carranza Leon B.G., Prokop L.J. et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 2015; 100(11): 4012–20. DOI: 10.1210/ jc.2015-2237
  16. Manson J.E., Chlebowski R.T., Stefanick M.L., Aragaki A.K., Rossouw J.E., Prentice R.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353–68. DOI: 10.1001/jama.2013.278040
  17. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. DOI: 10.1136/bmj.k4810
  18. Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология: национальное руководство. М.: ГЭОТАР-Медиа; 2017. 1008 с. [Savel'eva G.M., Sukhikh G.T., Serov V.N., Radzinskii V.E., Manukhin I.B., red. Ginekologiya: natsional'noe rukovodstvo. M.: GEOTAR-Media; 2017. 1008 s. (in Russian)]
  19. Atsma F., Bartelink M.L., Grobbee D.E., van der Schouw Y.T. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13(2): 265–79. DOI: 10.1097/01.gme.0000218683.97338.ea
  20. Lobo R.A., Bush T., Carr B.R., Pickar J.H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril. 2001; 76(1): 13–24. DOI: 10.1016/s0015-0282(01)01829-5
  21. Slopiena R. Wender-Ozegowskab E., Rogowicz-Frontczakcet A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6–10. DOI: 10.1016/j.maturitas.2018.08.009
  22. Kitchens C.S., Konkle B.A., Consultative C.M. Hemostasis and thrombosis. Philadelphia: Saunders; 2013. 840 p.
  23. Madigan D., Shin J. Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. Open Access J. Contracept. 2018; 9: 29–32. DOI: 10.2147/OAJC.S161737
  24. Карева Е.Н. Тромбозы и гестагены. Доктор.Ру. 2019; 7(162): 57–64. [Kareva E.N. Trombozy i gestageny. Doktor.Ru. 2019; 7(162): 57–64. (in Russian)]
  25. Fan X., Chen X., Wang C., Dai J., Lu Y., Wang K. et al. Drospirenone enhances GPIb-IX-V-mediated platelet activation. J. Thromb. Haemost. 2015; 13(10): 1918–24. DOI: 10.1111/jth.13109
  26. Piroga M., Jacha R., Undas A. Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 217: 77–82. DOI: 10.1016/j.ejogrb.2017.08.023

News

30 June 00:00
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 20, No. 5 (2021), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Marina Arkadievna Kinkulkina

28 June 00:00
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 4 (2021), Published

Find original articles and reviews covering various aspects of cardiology, gastroenterology, internal medicine and the interview with Professor Elena Zelikovna Golukhova

 

3 May 17:06
A New Issue of Doctor.Ru Pediatrics, Vol. 20, No. 3 (2021), Published

Find original articles and reviews covering various aspects of pediatrics and the interview with Professor Evgeny Grigorievich Furman

3 May 17:06
A New Issue of Doctor.Ru Endocrinology, Vol. 20, No. 2 (2021), Published

Find original articles and reviews covering various aspects of endocrinology and the interview with Professor Valentin Viktorovich Fadeev

16 April 11:57
Igor Evgenievich Khatkov joined the American Surgical Association

Igor Evgenievich Khatkov, Head of A. S. Loginov Moscow Clinical Scientific and Practical Centre, Chief Oncologist in and for Moscow is now an honoured member of the American Surgical Association.

All news